Amgen Inc. (AMGN)

203.21
1.45 0.71
NASDAQ : Health Technology
Prev Close 204.66
Open 204.15
Day Low/High 202.18 / 204.98
52 Wk Low/High 166.30 / 211.90
Volume 1.88M
Avg Volume 2.98M
Exchange NASDAQ
Shares Outstanding 599.70M
Market Cap 121.67B
EPS 12.70
P/E Ratio 16.05
Div & Yield 5.80 (2.82%)

Latest News

Amgen Foundation Launches Amgen Biotech Experience In Pittsburgh

Amgen Foundation Launches Amgen Biotech Experience In Pittsburgh

Unique Partnership With the Richard King Mellon Foundation Brings Renowned Science Education Program to Pittsburgh Area High School Students

Last Week's Portfolio Changes

We exited one position, initiated another and upgraded several names last week.

We’re Not Off to the Races Yet

According to one indicator, we may make a marginal new high before we get short-term overbought again, but I am not yet convinced that we have done enough work to break out of the range we’ve been in.

Weekly Roundup

A volatile week ends with heightened expectations for at least one more rate cut from the Fed.

Real Money Post-Industrial Average Continues to Outpace Major Indices

Real Money Post-Industrial Average Continues to Outpace Major Indices

RMPIA is up 20.9% in the first nine months of 2019.

Video: Jim's Daily Rundown for Tuesday

Jim discusses this morning's Amgen-AbbVie swap, UnitedHealth Group, and more!

We're Changing Pharmaceutical Names

We'll be using our Amgen funds to directly finance a purchase in AbbVie.

Amgen Downgraded, AbbVie Added to Bullpen

We see fewer pathways and catalysts that will get AMGN stock higher, and are downgrading our rating to a THREE, looking to sell into strength.

Amgen Announces New Clinical Data Evaluating Novel Investigational KRAS(G12C) Inhibitor In Patients With Solid Tumors At ESMO 2019

Amgen Announces New Clinical Data Evaluating Novel Investigational KRAS(G12C) Inhibitor In Patients With Solid Tumors At ESMO 2019

Responses Seen in Multiple Tumor Types With KRAS G12C Mutation

Weekly Roundup

Markets buffeted by impeachment turmoil and shift away from high-multiple growth names.

Heart Attack Survivors Are Taking Steps To Reduce Their Cardiovascular Risk. But Are They The Right Ones?

Heart Attack Survivors Are Taking Steps To Reduce Their Cardiovascular Risk. But Are They The Right Ones?

This World Heart Day, Amgen is Releasing Results of a Global Survey of 3,200 Heart Attack Survivors Conducted Across 13 Countries

Amgen To Webcast Investor Call At ESMO 2019

Amgen To Webcast Investor Call At ESMO 2019

THOUSAND OAKS, Calif., Sept.

Amgen Announces Positive Results From Two Phase 3 BLINCYTO® (blinatumomab) Studies In Pediatric Patients With Relapsed Acute Lymphoblastic Leukemia

Amgen Announces Positive Results From Two Phase 3 BLINCYTO® (blinatumomab) Studies In Pediatric Patients With Relapsed Acute Lymphoblastic Leukemia

Phase 3 '215 and Children's Oncology Group (COG) Studies Both Stopped Early Due to Treatment Benefit of BLINCYTO Over Chemotherapy

Amgen Looks Attractive After Its Recent Pullback

Amgen Looks Attractive After Its Recent Pullback

Amgen's AMG 510 phase 1 results helped change the narrative around the stock, but that was just the beginning.

Weekly Roundup

Markets traded mostly flat this week in spite of Saudi oil attacks, and a Fed rate cut, only turning sour on Friday on signs of renewed U.S. trade tensions with China.

Amgen Showcases New Data From Oncology Pipeline And Portfolio At ESMO 2019

Amgen Showcases New Data From Oncology Pipeline And Portfolio At ESMO 2019

New Data Show Clinical Responses in Colorectal and Appendiceal Cancer Patients Treated With AMG 510

S&P 500 Buybacks Decline Significantly In Q2 2019; Expenditures Still Remain Higher Than The Pre-2018 Levels

S&P 500 Buybacks Decline Significantly In Q2 2019; Expenditures Still Remain Higher Than The Pre-2018 Levels

- Q2 2019 share repurchases were $164.5 billion - 20.1% lower than Q1 2019, 13.7% lower than Q2 2018, and 26.2% lower than the record Q4 2018.

Markets Have a Strong Week on Sector Rotation, Reviving Chip Stocks

Easing trade tensions and steepening yield curve add to bulls' optimism.

Amgen Announces Phase 3 CANDOR Study Combining KYPROLIS® (carfilzomib) And DARZALEX® (daratumumab) Meets Primary Endpoint Of Progression-Free Survival

Amgen Announces Phase 3 CANDOR Study Combining KYPROLIS® (carfilzomib) And DARZALEX® (daratumumab) Meets Primary Endpoint Of Progression-Free Survival

First Phase 3 Study Combining KYPROLIS and DARZALEX, Two Critical Mechanisms of Action in Treatment of Multiple Myeloma

Amgen Highlights New Data From KYPROLIS® (carfilzomib) And Oncology Pipeline At IMW 2019

Amgen Highlights New Data From KYPROLIS® (carfilzomib) And Oncology Pipeline At IMW 2019

Data Presented From Anti-BCMA BiTE® and MCL-1 Programs

Jim Cramer: How to Survive This Violent Rotation

Jim Cramer: How to Survive This Violent Rotation

Emotions and panic must be checked at the door, if you are going to be a successful investor, especially right now.

Dow Finishes Higher; Wall Street Wavers Amid Expected Central Bank Stimulus

Dow Finishes Higher; Wall Street Wavers Amid Expected Central Bank Stimulus

Stocks finish mixed Monday as investors assess moves by the world's central banks to stimulate their economies.

Eli Lilly's Must-Hold Level on Drug-Data Pullback

Eli Lilly's Must-Hold Level on Drug-Data Pullback

Eli Lilly stock is falling on the day after releasing clinical trial data. Here's the must-hold spot for LLY stock now.

Could Small Drug Trial Hold Big Potential for Amgen?

Could Small Drug Trial Hold Big Potential for Amgen?

The results of a lung-cancer drug got me to go long on the stock, but the larger picture is complicated.

Video: Jim's Daily Rundown for Monday

Jim and Zev discuss the latest with U.S.-China trade relations, Amgen's 510 readout, and much more!.

Amgen Shares Tumble After Lung Cancer Treatment Update Misses Forecasts

Amgen Shares Tumble After Lung Cancer Treatment Update Misses Forecasts

Amgen shares traded lower Monday after the drugmaker presented details of a trial of its key lung cancer treatment that fell short of Wall Street forecasts.

Amgen Data Readout Fails to Live Up to Lofty Expectations

However, we see no change to our longer term view of the stock.

TheStreet Quant Rating: A- (Buy)